[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Intl Stem Cell Corp (ISCO)

Intl Stem Cell Corp (ISCO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Intl Stem Cell Corp 9745 BUSINESSPARK AVENUE SAN DIEGO CA 92131 USA

www.internationalstemcell.com Employees: 33 P: 760-940-6383

Sector:

Medical

INDUSTRY GROUPING:

Medical - Biomedical

Description:

International Stem Cell Corporation is a biotechnology company currently focused on developing therapeutic and research products. In the area of therapeutic product development, ISCO's objective is to create an unlimited source of human cells for use in the treatment of several diseases, including diabetes, liver disease and retinal disease through cell transplant therapy. In furtherance of this objective, ISCO has developed pluripotent human stem cells from unfertilized human eggs, and techniques to cause those stem cells to be differentiated into the specific cell types required for transplant. It has developed manufacturing protocols to produce the cells minimizing contamination with animal by-products, a characteristic likely to be important in meeting U.S. Food and Drug Administration requirements. ISCO also provides the specialized cells and growth media needed for therapeutic cell transplantation research to academic and commercial researchers in related fields.

Key Statistics

Overview:

Market Capitalization, $K 2,241
Enterprise Value, $K 1,261
Shares Outstanding, K 8,004
Float, K 2,260
% Float 28.23%
Short Interest, K 7
Short Float 0.08%
Days to Cover 1.00
Short Volume Ratio 0.47
% of Insider Shareholders 71.77%
% of Institutional Shareholders 0.00%

Financials:

Annual Sales, $ 9,100 K
Annual Net Income, $ -420 K
Last Quarter Sales, $ 2,320 K
Last Quarter Net Income, $ -220 K
EBIT, $ -240 K
EBITDA, $ -20 K

Growth:

1-Year Return 107.81%
3-Year Return 133.33%
5-Year Return -62.16%
5-Year Revenue Growth 27.63%
5-Year Earnings Growth 86.11%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.03 on 05/14/26
Next Earnings Date 08/13/26 [--]
Earnings Per Share ttm -0.06
EPS Growth vs. Prev Qtr 25.00%
EPS Growth vs. Prev Year 0.00%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%
Most Recent Split 1-150 on 07/29/15

ISCO Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % -8.55%
Profit Margin % -4.62%
Debt/Equity 0.00
Price/Sales 0.15
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share -0.53
Interest Coverage -1.80
60-Month Beta -0.01
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.